Abstract
Abstract
Background
Flunixin meglumine (FM) was investigated for the effectiveness of plasma, oral fluid, and urine concentrations to predict tissue residue depletion profiles in finishing-age swine, along with the potential for untreated pigs to acquire tissue residues following commingled housing with FM-treated pigs. Twenty pigs were housed in groups of three treated and one untreated control. Treated pigs received one 2.2 mg/kg dose of FM intramuscularly. Before treatment and at 1, 3, 6, 12, 24, 36, and 48 h (h) after treatment, plasma samples were taken. At 1, 4, 8, 12 and 16 days (d) post-treatment, necropsy and collection of plasma, urine, oral fluid, muscle, liver, kidney, and injection site samples took place. Analysis of flunixin concentrations using liquid chromatography/tandem mass spectrometry was done. A published physiologically based pharmacokinetic (PBPK) model for flunixin in cattle was extrapolated to swine to simulate the measured data.
Results
Plasma concentrations of flunixin were the highest at 1 h post-treatment, ranging from 1534 to 7040 ng/mL, and were less than limit of quantification (LOQ) of 5 ng/mL in all samples on Day 4. Flunixin was detected in the liver and kidney only on Day 1, but was not found 4–16 d post-treatment. Flunixin was either not seen or found less than LOQ in the muscle, with the exception of one sample on Day 16 at a level close to LOQ. Flunixin was found in the urine of untreated pigs after commingled housing with FM-treated pigs. The PBPK model adequately correlated plasma, oral fluid and urine concentrations of flunixin with residue depletion profiles in liver, kidney, and muscle of finishing-age pigs, especially within 24 h after dosing.
Conclusions
Results indicate untreated pigs can be exposed to flunixin by shared housing with FM-treated pigs due to environmental contamination. Plasma and urine samples may serve as less invasive and more easily accessible biological matrices to predict tissue residue statuses of flunixin in pigs at earlier time points (≤24 h) by using a PBPK model.
Funder
Iowa Pork Producers Association
National Pork Board
National Institute of Food and Agriculture
Publisher
Springer Science and Business Media LLC
Subject
General Veterinary,General Medicine
Reference42 articles.
1. Merck Animal Health Banamine-S Flunixin Meglumine Label (Injectable Solution Veterinary). 2020. Available at: https://www.merck-animal-health-usa.com/pdfs/swine/Banamine-S_product_bulletin_tcm96-161528.pdf (last accessed date: February 06, 2020).
2. The Veterinarian’s Guide to Residue Avoidance Management (VetGRAM). Food Animal Residue Avoidance Databank (A component of the Food Animal Residue Avoidance & Depletion Program). Available at: http://www.farad.org/vetgram/search.asp. Accessed 6 Feb 2020.
3. Buur JL, Baynes RE, Smith G, Riviere JE. Pharmacokinetics of flunixin meglumine in swine after intravenous dosing. J Vet Pharmacol Ther. 2006;29(5):437–40.
4. Hardie EM, Hardee GE, Rawlings CA. Pharmacokinetics of flunixin meglumine in dogs. Am J Vet Res. 1985;46(1):235–7.
5. Welsh EM, McKellar QA, Nolan AM. The pharmacokinetics of flunixin meglumine in the sheep. J Vet Pharmacol Ther. 1993;16(2):181–8.